Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.7300
-0.0791 (-9.78%)
At close: Jan 22, 2026, 4:00 PM EST
0.7205
-0.0095 (-1.30%)
Pre-market: Jan 23, 2026, 6:59 AM EST
Jaguar Health Revenue
Jaguar Health had revenue of $3.08M in the quarter ending September 30, 2025, a decrease of -0.80%. This brings the company's revenue in the last twelve months to $11.79M, up 13.37% year-over-year. In the year 2024, Jaguar Health had annual revenue of $11.69M with 19.75% growth.
Revenue (ttm)
$11.79M
Revenue Growth
+13.37%
P/S Ratio
0.07
Revenue / Employee
$240,510
Employees
49
Market Cap
3.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.69M | 1.93M | 19.75% |
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
| Dec 31, 2018 | 4.42M | 54.96K | 1.26% |
| Dec 31, 2017 | 4.36M | 4.22M | 2,981.61% |
| Dec 31, 2016 | 141.52K | -116.86K | -45.23% |
| Dec 31, 2015 | 258.38K | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 4.49M |
| Lyra Therapeutics | 600.00K |
| HCW Biologics | 422.03K |
| PMGC Holdings | 285.95K |
| Cardio Diagnostics Holdings | 15.78K |
JAGX News
- 22 hours ago - Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi - Accesswire
- 8 days ago - Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts - Accesswire
- 10 days ago - Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million - Accesswire
- 16 days ago - Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication - Accesswire
- 20 days ago - Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Accesswire
- 5 weeks ago - Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Accesswire
- 6 weeks ago - FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs - Accesswire
- 6 weeks ago - Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders - Accesswire